




RealRate

PHARMACEUTICAL 2017

Chinook Therapeutics INC
Rank 161 of 308



The relative strengths and weaknesses of Chinook Therapeutics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Chinook Therapeutics INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 37% points. The greatest weakness of Chinook Therapeutics INC is the variable Other Liabilities, reducing the Economic Capital Ratio by 108% points.

The company's Economic Capital Ratio, given in the ranking table, is 249%, being 4.1% points above the market average of 245%.

Input Variable	Value in 1000 USD
Assets, Current	354,764
Cost of Goods Sold	0
Intangible Assets	35,485
Liabilities, Current	30,632
Liabilities, Non-Current	1,109
Other Assets	21,978
Other Compr. Net Income	-1,345
Other Expenses	22,013
Other Liabilities	179,650
Other Net Income	2,179
Other Revenues	50,681
Property and Equipment	26,384
Research and Development	87,718
Selling, General and Administrative Expense	34,277

Output Variable	Value in 1000 USD
Assets	438,611
Liabilities	211,391
Expenses	144,008
Revenues	50,681
Stockholders Equity	227,220
Net Income	-91,148
Comprehensive Net Income	-91,820
BaseVar	424,108
ECR before LimitedLiability	124%
Economic Capital Ratio	249%